Value
0.0/10data confidence 20%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
- ▸Expensive valuation
MESO · Why this verdict
Why Mesoblast (MESO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company burns cash at a rate exceeding 100% of revenues, has no reported operating or net margin, and generates no return on equity or assets — the hallmarks of a pre-commercial business that has not yet demonstrated an economically viable path to profitability. Quality breakdown | Operating margin turns positive and cash burn falls below 50% of revenues within 12 months, indicating meaningful progress toward commercial sustainability. | →Stable |
| CounterPre-commercial biotechs are valued on pipeline potential rather than current financials; the near-term liquidity position (current ratio of 5.7) suggests the company has sufficient capital to continue operations through the next catalyst, making the current cash burn a known and managed condition. | ||
At current prices there is approximately 116% potential upside to the analyst consensus price target versus roughly 3.4% geometric downside, producing a reward-to-risk ratio of more than 34-to-1 — an extreme asymmetry that justifies monitoring even in the absence of a confirmed entry signal. Price targets | Price advances at least 50% toward the $29.75 consensus target within 12 months as a catalyst narrows the gap between current price and the analyst estimate of intrinsic value. | →Stable |
| CounterExtreme reward-to-risk ratios on falling-knife names often reflect permanent capital impairment risk rather than opportunity; a ratio of 34-to-1 exists because the market assigns a high probability of the thesis failing entirely, not because the downside is genuinely bounded at 3.4%. | ||
The stock is in a falling-knife formation — below all moving averages with a bearish MACD, a declining on-balance volume trend, a death cross, and a momentum score well below the minimum threshold — indicating sustained distribution and the absence of a technical setup that would support an entry. V9 | Momentum score recovers above 4.5 and the stock closes above its 200-day moving average for 4 consecutive weeks within 12 months, signaling a technical reversal. | →Stable |
| CounterThe current RSI near 39 is approaching oversold territory, and biotech share prices can reverse sharply on binary catalysts regardless of technical formation; waiting for technical confirmation may mean missing the bulk of any recovery. | ||
Sell-side analysts collectively point to more than 154% upside from current prices, implying that professional fundamental research sees substantial unrealized value that the market has not yet recognized — a gap that, if it closes even partially, would represent a material return. Sentiment breakdown | Analyst consensus price target remains above $25.00 and at least one new initiation or reiteration with a bullish outlook is published within the next 12 months. | →Stable |
| CounterAnalyst price targets on small biotechs carry limited predictive value; coverage can be thin and models depend almost entirely on binary regulatory and clinical outcomes that are inherently uncertain, making the consensus upside figure a wide-confidence-interval estimate rather than a reliable anchor. | ||
The company burns cash at a rate exceeding 100% of revenues, has no reported operating or net margin, and generates no return on equity or assets — the hallmarks of a pre-commercial business that has not yet demonstrated an economically viable path to profitability.
→StableQuality breakdown
- Expectation
- Operating margin turns positive and cash burn falls below 50% of revenues within 12 months, indicating meaningful progress toward commercial sustainability.
CounterPre-commercial biotechs are valued on pipeline potential rather than current financials; the near-term liquidity position (current ratio of 5.7) suggests the company has sufficient capital to continue operations through the next catalyst, making the current cash burn a known and managed condition.
At current prices there is approximately 116% potential upside to the analyst consensus price target versus roughly 3.4% geometric downside, producing a reward-to-risk ratio of more than 34-to-1 — an extreme asymmetry that justifies monitoring even in the absence of a confirmed entry signal.
→StablePrice targets
- Expectation
- Price advances at least 50% toward the $29.75 consensus target within 12 months as a catalyst narrows the gap between current price and the analyst estimate of intrinsic value.
CounterExtreme reward-to-risk ratios on falling-knife names often reflect permanent capital impairment risk rather than opportunity; a ratio of 34-to-1 exists because the market assigns a high probability of the thesis failing entirely, not because the downside is genuinely bounded at 3.4%.
The stock is in a falling-knife formation — below all moving averages with a bearish MACD, a declining on-balance volume trend, a death cross, and a momentum score well below the minimum threshold — indicating sustained distribution and the absence of a technical setup that would support an entry.
→StableV9
- Expectation
- Momentum score recovers above 4.5 and the stock closes above its 200-day moving average for 4 consecutive weeks within 12 months, signaling a technical reversal.
CounterThe current RSI near 39 is approaching oversold territory, and biotech share prices can reverse sharply on binary catalysts regardless of technical formation; waiting for technical confirmation may mean missing the bulk of any recovery.
Sell-side analysts collectively point to more than 154% upside from current prices, implying that professional fundamental research sees substantial unrealized value that the market has not yet recognized — a gap that, if it closes even partially, would represent a material return.
→StableSentiment breakdown
- Expectation
- Analyst consensus price target remains above $25.00 and at least one new initiation or reiteration with a bullish outlook is published within the next 12 months.
CounterAnalyst price targets on small biotechs carry limited predictive value; coverage can be thin and models depend almost entirely on binary regulatory and clinical outcomes that are inherently uncertain, making the consensus upside figure a wide-confidence-interval estimate rather than a reliable anchor.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Mesoblast offers an extraordinary gap between current price and analyst consensus — over 116% potential upside at roughly 34-to-1 reward versus geometric downside — but the stock is in a falling-knife formation, burns cash at over 100% of revenues, operates with zero reported margins, and quality scores well below minimum thresholds; the asymmetric geometry is notable but the entry setup is not confirmed.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Op margin | 0.0 |
| Current ratio | 5.7 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -106% of revenue
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.2 |
| OBV | 10.0 |
| MA position | 4.5 |
| Volume | 0.5 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 5.9 |
| Price target | 10.0 |
- ▸Light analyst coverage (2.0) — signal dampened
- ▸Analyst upside: 144%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 5.0 |
- ▸Heavy insider buying — $26,172,070 (1.408% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.2 |
| quality rank | 3.5 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 5.5 |
| 52w position | 3.3 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.4 |
| days to cover | 0.0 |
| volatility | 1.1 |
| put call | 8.3 |
| implied vol | 0.0 |
| beta | 8.2 |
| debt equity | 9.1 |
| news risk | 6.0 |
- ▸High IV: 145%
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 6.8 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.1>=4.5
- ASYMMETRY:11.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:53d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
- DEATH_CROSS:momentum=5.1>=5.0 recovering
Reward-to-Risk
11.80
Upside
+107.6%
Downside
9.1%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 53
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Insider at 7.3 could not lift the engine output above the verdict floor.
The strongest dimensions are Insider at 7.3, Sentiment at 7.0, and Catalyst at 6.3; the weakest are Value at 0.0, Quality at 2.3, and Peer rank at 3.9. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 11.80 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Asymmetric Upside Geometry
Trip ifAnalyst consensus price target is cut below $20.00, reducing implied upside to less than 45% from current levels.
- P2Falling Knife Technical Profile
Trip ifMomentum score recovers above 4.5 and price closes above its 200-day moving average for 4 consecutive weeks.
- P3Cash Burn Zero Margin Profile
Trip ifOperating margin rises above 0% for 2 consecutive reporting periods.
- P4Large Analyst Consensus Upside
Trip ifAnalyst consensus price target falls below $22.00.